The Role of the Iron-Chelating Agent Deferoxamine in Spinal Cord Injury: A Systematic Review and Meta-Analysis of Preclinical Studies.

Background context: Despite advances in the medical, surgical and rehabilitation treatment of spinal cord injury (SCI), there is a need to develop therapeutic strategies to address mechanisms of secondary injury. Numerous preclinical studies investigated deferoxamine efficacy, an iron chelating agent, in improving functional outcome in SCI models. They proposed anti-inflammatory, anti-ferroptosis, and lipoperoxidation inhibitory mechanisms as the underlying mechanism of action.

Purpose: Considering preclinical studies are the gate to translational medicine, we present a quantitative synthesis of the existing literature to shed light on gaps and guide future research in neuroprotection for SCI.

Study design: This is a meta-analysis of preclinical studies involving the use of deferoxamine in in-vivo models of traumatic SCI, regardless of level of injury and/or animal species.

Methods: We conducted a comprehensive search in 3 databases (PubMed, Web of Science, Scopus) in accordance with PRISMA guidelines. Our review protocol was preregistered (PROSPERO registration ID: CRD420251007113). Ten preclinical studies that investigated deferoxamine administration in functional outcome of animals were chosen. We performed a meta-analysis, using a random effects approach, comparing normalized mean differences in deferoxamine-treated and control group. To minimize heterogeneity, subgroup analysis and meta regression were conducted. We utilized the CAMARADES checklist for quality assessment of the included studies.

Results: Out of 157 articles, 10 were included for final analysis. Our results revealed that deferoxamine can improve functional scores in animal models of thoracic traumatic SCI (NMD=35.74% [18.74, 52.75]; p<0.001). The funnel plot was symmetric and no publication bias was noted. Heterogeneity was high among included studies (I²: 95.98). The median score for CAMARADES was 5 (IQR range: 4-6), indicating moderate overall quality of include studies. Sample size calculation and allocation concealment were lacking in included studies. Meta regression was significant for assessment time (Coefficient: -0.574 [-0.905, -0.242]) and route of administration.

Conclusion: We demonstrated that deferoxamine improves hindlimb motor function in animal models of SCI. Potential knowledge gaps exist, necessitating future animal studies across a more diverse range of injury level and function assessment tools before moving on to conducting clinical trials. Assessment time may play a critical role in preclinical models and needs to be adjusted to clinically plausible time points in future studies. More inter-species preclinical research, especially in non-human primates, is encouraged to foster generalizability and clinical applicability of the models.

Clinical significance: Approved medical interventions for neuroprotection in SCI are lacking. Given the promising results of the included preclinical studies as well as the established clinical safety profile of deferoxamine, our paper provides a basic science foundation for the design and implementation of future randomized controlled trials. Notwithstanding, these trials may be withheld or approached with caution until more extensive preclinical research is available. .